Regulatory strategy · EU MDR · US FDA
Bring medical devices to market through a controlled regulatory route
Align intended purpose, classification, evidence, quality processes and market submissions before late regulatory decisions force redesign or repeated testing.
Product boundary
Start with what the manufacturer intends the product to do
A device name or sales category does not determine the regulatory route. Qualification begins with the intended medical purpose, principal mode of action, users, patient population, use environment and claims.
Non-invasive products
Simple does not mean unregulated
Dressings, supports, collection systems, accessories and other non-invasive products still require documented qualification, classification, risk management, evidence, labeling and market-specific records.
Active equipment
Energy, monitoring and treatment change the risk analysis
Diagnostic equipment, therapeutic systems, monitors, pumps and electrically powered devices require attention to active-device rules, electrical safety, electromagnetic compatibility, usability and software where applicable.
Invasive and implantable products
Contact, duration and anatomy drive classification
Invasiveness, contact site, duration, biological effect, absorption and interaction with medicinal substances can materially change the class, conformity assessment and clinical-evidence burden.
Implantable-device servicesSoftware and connected systems
Information can itself create medical risk
Standalone software, embedded software, connected functions and AI-enabled features need a defined regulatory boundary, software lifecycle controls, cybersecurity evidence and claim-aligned validation.
Medical-software servicesIn vitro diagnostic medical devices follow the separate IVDR framework in the European Union. See the dedicated IVD regulatory services page.
Early decisions
Resolve the regulatory architecture before verification begins
These decisions determine which requirements, studies, quality processes, submissions and external reviewers belong in the development plan.
- 01
What is the exact intended purpose?
Define the medical purpose, target population, users, use environment, indications, limitations and principal mode of action.
- 02
Which regulatory category and class apply?
Document qualification, classification rule or FDA product code, applicable controls and any borderline considerations.
- 03
Which evidence is needed?
Translate claims and risks into verification, validation, biocompatibility, electrical, software, usability, cybersecurity and clinical evidence.
- 04
Which external route is required?
Confirm notified-body involvement, FDA submission type, authorised representative needs and authority interactions.
- 05
How will the product be maintained?
Plan change control, suppliers, complaints, vigilance, PMS, cybersecurity updates, registrations and evidence updates from the outset.
European Union
Build the MDR route from intended purpose and inherent risk
Regulation (EU) 2017/745 divides devices into classes I, IIa, IIb and III. The applicable Annex VIII rule, device features and claims determine both the class and the available conformity-assessment routes.
Class I
Non-sterile, non-measuring class I devices that are not reusable surgical instruments can generally be self-declared. The manufacturer still needs complete technical documentation and an effective quality system.
Class I with notified-body involvement
A notified body assesses the sterile, measuring or reusable-surgical- instrument aspects within the scope defined by the MDR.
Classes IIa and IIb
Notified-body conformity assessment is required. The route and depth of technical-documentation assessment depend on the class, device group, technology and selected conformity-assessment annex.
Class III
Class III devices require notified-body assessment of the QMS and technical documentation, with the most demanding clinical and lifecycle evidence and additional procedures for certain device categories.
A manufacturer established outside the Union must appoint a sole EU authorised representative for devices of the same generic device group.
The first four declared-functional EUDAMED modules have been mandatory since 28 May 2026, including actor and UDI/device registration modules.
PMS, vigilance, clinical evaluation, PMCF where applicable and risk management must remain connected after the CE mark is affixed.
United States
Identify the FDA product code before choosing the submission
FDA class alone does not identify the complete pathway. The classification regulation, product code, intended use, technology, predicates and exemption limitations determine the applicable controls and premarket route.
No premarket submission where the exemption applies
An exemption from 510(k) does not by itself remove applicable general controls or other requirements. Confirm the exact classification regulation and the limitations of exemption before relying on this route.
Substantial equivalence to a legally marketed predicate
The submission must support the intended use, technological comparison, performance testing and substantial-equivalence conclusion for the proposed device.
Novel low-to-moderate-risk device type
De Novo provides a classification route when no legally marketed predicate exists and general controls alone, or general and special controls, can reasonably assure safety and effectiveness.
High-risk devices requiring premarket approval
PMA requires valid scientific evidence supporting reasonable assurance of safety and effectiveness, together with manufacturing and quality information.
Classification and controls
Confirm the product code, class, regulation, general controls, special controls and submission status.
Evidence and FDA interaction
Plan performance and clinical evidence, predicate strategy and Pre-Submission interaction where useful.
QMSR readiness
The FDA Quality Management System Regulation became effective on 2 February 2026 and incorporates ISO 13485:2016 by reference.
Registration and lifecycle duties
Complete establishment registration and device listing when applicable and maintain reporting, corrections, removals and quality obligations.
FDA establishment registration and device listing do not constitute clearance or approval. When a premarket submission is required, the appropriate clearance, grant or approval must be obtained before marketing.
Evidence architecture
Make one evidence system serve development and market access
A reusable evidence core reduces duplication only when product identity, configurations, claims, risks and acceptance criteria remain controlled.
Product definition
Intended purpose, indications, users, patients, principles of operation, configurations, accessories and market claims.
Risk management
Hazard analysis, benefit-risk conclusions, risk controls, verification links and residual-risk communication throughout the lifecycle.
Design verification and validation
Bench performance, biological safety, electrical safety, EMC, sterilization, packaging, usability, software and cybersecurity as applicable.
Clinical evidence
Clinical evaluation or FDA clinical strategy tied to intended purpose, claims, state of the art, residual risks and evidence gaps.
Manufacturing and quality controls
Controlled processes, suppliers, specifications, validation, release, nonconformity, CAPA and change management.
Post-market system
Complaints, PMS, vigilance or medical device reporting, trend analysis, PMCF where applicable and evidence updates.
MDRC delivery model
Move from an uncertain product route to a controlled submission programme
MDRC can resolve one regulatory question or coordinate the complete route with your engineering, quality, clinical, laboratory and commercial teams.
- 01
Define the product
Confirm intended purpose, variants, accessories, users, claims, markets and regulatory boundaries.
- 02
Set the strategy
Document qualification, classification, submission or conformity-assessment route, stakeholders and critical assumptions.
- 03
Assess readiness
Review existing QMS, technical documentation, testing, clinical evidence, labeling and registrations against the selected route.
- 04
Close evidence gaps
Prepare requirements, study plans, protocols, documentation and supplier inputs needed for a reviewable dossier.
- 05
Manage external review
Support notified-body or FDA interactions, submission questions, remediation and controlled evidence updates.
- 06
Maintain market compliance
Integrate PMS, vigilance, reporting, registrations, change assessment and periodic evidence review.
Qualification and classification
Product boundary, class rationale and market pathway.
→ DocumentationTechnical documentation
Structure, gap assessment, preparation and remediation.
→ RepresentationEU authorised representative
Representation for manufacturers established outside the EU.
→ ComplianceEU PRRC services
Independent regulatory-compliance oversight under MDR Article 15.
→Primary sources
Confirm the route against current authority requirements
Regulation (EU) 2017/745
Official MDR text, including classification and conformity assessment
MDCG classification guidance
Current European Commission guidance on applying the MDR classification rules
EUDAMED overview
Current module status and mandatory-use information
FDA device market pathways
Classification, premarket routes and general regulatory controls
FDA Quality Management System Regulation
Current QMSR requirements effective since 2 February 2026
Frequently asked questions
Practical market-access distinctions
The exact route must be confirmed against the released device, intended use, technology, risk, evidence and target-market requirements.
Does every medical device need a notified body in the EU?
No. A class I device that is not sterile, does not have a measuring function and is not a reusable surgical instrument can generally be self-declared. Classes IIa, IIb and III and the relevant aspects of class Is, Im and Ir devices require notified-body involvement.
Does every medical device require an FDA 510(k)?
No. Depending on the product code and classification regulation, a device may be exempt, use 510(k), follow De Novo or require PMA. Exemption limitations and other applicable controls must still be checked.
Is FDA registration the same as clearance or approval?
No. Establishment registration and device listing do not constitute FDA clearance or approval. A required premarket clearance, grant or approval must be obtained before marketing.
Can one technical file support the EU and US?
A controlled evidence core can often support both markets, but dossier structure, classification, labeling, regulatory decisions and market-specific records differ. Plan reuse before assembling the submissions.
When should regulatory strategy begin?
Before intended purpose, design inputs, claims and verification plans are fixed. Early pathway decisions reduce unsuitable testing, missing evidence and late redesign.
Define the route
Turn the device concept into a workable regulatory programme
Send us the intended purpose, device description, development status, target markets and existing evidence. We will identify the critical regulatory decisions and propose a focused scope of work.
Map your device pathway